The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

32 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
16
Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).EBI
Ontario Institute For Cancer Research
19
Structure-Based Design of¿-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.EBI
University of Michigan
17
SAH derived potent and selective EZH2 inhibitors.EBI
Pfizer
25
Discovery of a selective, substrate-competitive inhibitor of the lysine methyltransferase SETD8.EBI
University of North Carolina at Chapel Hill
13
Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening.EBI
Chinese Academy of Sciences
6
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2.EBI
TBA
20
Discovery of WDR5-MLL1 and HDAC Dual-Target Inhibitors for the Treatment of Acute Myeloid Leukemia.EBI
China Pharmaceutical University
11
An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.EBI
UNC Eshelman School of Pharmacy
2
Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.EBI
Daiichi Sankyo Co., Ltd
40
Discovery of a Highly Potent and Selective Inhibitor Targeting Protein Lysine Methyltransferase NSD2.EBI
Sun Yat-Sen University
31
Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors.EBI
Sun Yat-Sen University
26
Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase.EBI
University of California San Francisco
27
Structure-Based Design and Characterization of the Highly Potent and Selective Covalent Inhibitors Targeting the Lysine Methyltransferases G9a/GLP.EBI
Sun Yat-Sen University
17
Discovery of a New-Generation S-Adenosylmethionine-Noncompetitive Covalent Inhibitor Targeting the Lysine Methyltransferase Enhancer of Zeste Homologue 2.EBI
Sun Yat-Sen University
47
Structural Modification and Pharmacological Evaluation of Substituted Quinoline-5,8-diones as Potent NSD2 Inhibitors.EBI
Shanghai Jiao Tong University
10
Computational methods-guided design of modulators targeting protein-protein interactions (PPIs).EBI
Shanghai Jiao Tong University
38
Structure-Aided Design, Synthesis, and Biological Evaluation of Potent and Selective Non-Nucleoside Inhibitors Targeting Protein Arginine Methyltransferase 5.EBI
Sun Yat-Sen University
11
Targeting WD Repeat-Containing Protein 5 (WDR5): A Medicinal Chemistry Perspective.EBI
China Pharmaceutical University
17
Small-Molecule Inhibitors of the MLL1 CXXC Domain, an Epigenetic Reader of DNA Methylation.EBI
University of Virginia
2
Discovery of EBI
China Pharmaceutical University
27
Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.EBI
China Pharmaceutical University
44
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma.EBI
Chinese Academy of Sciences
9
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.EBI
China Pharmaceutical University
1
Engineering Fluorine into Verticillins (Epipolythiodioxopiperazine Alkaloids) via Precursor-Directed Biosynthesis.EBI
University of North Carolina At Greensboro
11
Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.EBI
China Pharmaceutical University
33
Methyllysine binding domains: Structural insight and small molecule probe development.EBI
University of Connecticut
65
NON-ACID INHIBITORS OF INOSITOL HEXAKISPHOSPHATE KINASE (IP6K) AND METHODS OF USE THEREOFBDB
Lieber Institute
52
LONP1 INHIBITOR COMPOUNDS, USES AND METHODSBDB
Pretzel Therapeutics
73
Bicyclic DGK InhibitorsBDB
Incyte
1030
CARM1 INHIBITORS AND USES THEREOFBDB
Epizyme
143
Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereofBDB
280 Bio
19
Morpholine derivativeBDB
Hoffmann-La Roche